Effector T Cell Egress via Afferent Lymph Modulates Local Tissue Inflammation

Daniela Gómez, Malissa C. Diehl, Erika J. Crosby, Tiffany Weinkopff and Gudrun F. Debes

*J Immunol* published online 9 September 2015
http://www.jimmunol.org/content/early/2015/09/09/jimmunol.1500626

Supplementary Material  http://www.jimmunol.org/content/suppl/2015/09/09/jimmunol.1500626.6.DCSupplemental

Subscription  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Effector T Cell Egress via Afferent Lymph Modulates Local Tissue Inflammation

Daniela Gómez, Malissa C. Diehl, Erika J. Crosby, Tiffany Weinkopf, and Gudrun F. Debes

Memory/effector T cells recirculate through extralymphoid tissues by entering from blood and exiting via afferent lymph. Although T cell entry into effector sites is key to inflammation, the relevance of T cell egress to this process is unknown. In this study, we found that Ag recognition at the effector site reduced the tissue egress of proinflammatory Th1 cells in a mouse model of delayed hypersensitivity. Transgenic expression of “tissue exit receptor” CCR7 enhanced lymphatic egress of Ag-sequestered Th1 cells from the inflamed site and alleviated inflammation. In contrast, lack of CCR7 on Th1 cells diminished their tissue egress while enhancing inflammation. Lymph-borne Th1 and Th17 cells draining the inflamed skin of sheep migrated toward the CCR7 ligand CCL21, suggesting the CCR7-CCL21 axis as a physiological target in regulating inflammation. In conclusion, exit receptors can be targeted to modulate T cell dwell time and inflammation at effector sites, revealing T cell tissue egress as a novel control point of inflammation.

The Journal of Immunology, 2015, 195: 000–000.

During immunosurveillance and inflammation, effector/memory T cells, unlike naïve T cells, recirculate through extralymphoid tissues, entering from the blood and exiting via the afferent lymph (1). From the afferent lymph, T cells reach regional lymph nodes, which they leave via the efferent lymph, returning them back into blood. T cell migration into tissues is regulated by a multistep cascade involving adhesion and chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2). Similarly, T cell egress from lymph nodes is controlled by chemokine receptors on T cells interacting with their respective endothelial ligands (2).

Congruently, lymphatic endothelial cells constitutively express the CCR7 ligand CCL21 in many organs (6). T cell entry into effector sites is critical for inflammation and is a target of anti-inflammatory therapy (7). Given the large number of lymphocytes, including proinflammatory Th1 and Th17 cells, that egress from chronically inflamed sites (8, 9), T cell egress potentially determines effector T cell accumulation and their downstream effector functions in situ. During inflammation and infection, the CCR7-CCL21 receptor-ligand pair guides T cells out of affected tissues via afferent lymph (5, 9, 10), and CCR7 deficiency promotes the development of long-term tissue-resident memory T cells (TRem) key to site-specific immunity (11). However, inflammation also facilitates CCR7-independent T cell tissue egress (9, 12) with contributions from additional chemokine receptors, such as sphingosine-1 phosphate (9, 13).

CCR7−/− mice demonstrate exacerbated inflammation in various models, such as cutaneous hypersensitivity (14), chronic arthritis (15), gastrointestinal inflammation (16, 17), and autoimmunity (reviewed in Ref. 18), suggesting a role of T cell egress in regulating tissue inflammation. Conversely, mice with transgenic expression of Ccr7 (Ccr7TG) exhibit reduced effector responses (19). Nevertheless, in these models, it is impossible to dissect the role of T cell egress in inflammation, in particular as other anomalies contribute to the observed phenotypes, for example, regulatory T cell defects in Ccr7−/− mice (14, 20) or retention of Ccr7TG T cells in splenic white pulp (19). As a result, although discussed previously (9, 16, 17, 21), the role of T cell egress in the modulation of tissue inflammation remains unresolved.

In this study, we revisited this question and demonstrate that targeting the tissue egress capacity of proinflammatory T cells modulates the local inflammatory response, enhancing our understanding of the pathogenesis of inflammation and laying the foundation for future therapies for inflammatory diseases.

Materials and Methods

Animals and surgical procedures in sheep

All mice were on C57BL/6 background, bred in our animal facility, and used between 8 and 16 wk of age in male and female sex- and age-matched groups. CD45.1 and CD45.2 congenic mice and OTII mice were obtained from The Jackson Laboratory, Ccr7−/− mice (22) were from Martin Lipp (Max Delbrück Center), Ccr7TG mice (23) from Nigel Killeen (University of California, San Francisco, San Francisco, CA [UCSF]), and CMTM mice (24) from Avinash Bhandoola (National Institutes of Health, National Cancer Institute, Bethesda, MD). OTII mice were crossed with Ccr7−/− and with Ccr7TG mice to obtain Ccr7−/− OTII and Ccr7TG OTII mice, respectively. Ccr7−/− OTII and Ccr7TG OTII breeders, but not their offspring, were maintained on an antibiotic diet (Mouse Helicobacter MD’s 4 Drug
Combio, Bio-Serv). For sheep experiments, 5- to 10-mo-old female mixed breed or Dorset sheep were purchased from Animal Biotech Industries or Pine Ridge Dorsets, respectively. Skin draining "pseudoafferent" lymph vessels were induced by lymphadenectomy of the subiliac (prefemoral) lymph nodes as detailed previously (25). Pseudoafferent (prenodal) skin draining lymph vessels were cannulated with heparin-coated sterile catheters (Carmelida) in a surgical procedure under isoflurane anesthesia as described previously (9, 25). Lymph was collected from unanesthetized animals into sterile collection bottles containing heparin (APh Pharma- ceuticals, LLC). All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

Cell isolation, culture, and labeling and chemotaxis assay

Lymphocytes were isolated from lymph nodes and spleens by passage through 40-μm cell strainers (BD Biosciences), as described previously (10). RBCs were lysed with 160 mM ammonium chloride, and cells were washed in RPMI 1640 with 10% FBS. Th1 cells were generated from microbead-sorted (Miltenyi Biotech) CD4+ T cells cultured on plate-bound anti-CD3 (145-2C11; UCSC Monoclonal Antibody Core (UCSF MAC) and anti-CD28 (37.51; UCSF MAC) in the presence of IL-12 (R&D Systems), IFN-γ (R&D Systems), and anti-IL-4 (11B11; BioXCell) as described previously (9). On day 5 of culture, dead cells were removed using a Nycodenz gradient (Axis-Shield). Th1 cells were labeled with 0.5 mM CFSE (Life Sciences) or 5 mM eFluor670 (eFluor; eBioscience) in HBSS at 37˚C with 0.1 mg/ml DNase I (Roche) and 12.5 μg/ml OVA protein (Sigma-Aldrich). Cells were isolated from footpad skin by mouse TNFα were pulsed overnight with 500 ng/ml LPS (Sigma-Aldrich), 10 ng/ml anti-OVA protein (Sigma-Aldrich) or OVA protein (Sigma-Aldrich). Cells were isolated from footpad skin by mincing mouse feet followed by two 30-min enzymatic digestion steps in HBSS at 37˚C with 0.1 mg/ml DNase I (Roche) and 12.5 μg/ml Liberase TM (Roche). Subsequently, samples were passed through a 100-μm cell strainer. The chemotaxis assay was carried out and analyzed as described previously (26). In brief, 5 × 104 lymph-borne cells in RPMI 1640 containing 10% FBS were added to the upper chamber of 5-μm pore size Transwell inserts (Corning). Mouse CCL21 (R&D Systems) was added to the lower chamber at 100 nM, its optimal concentration to attract ovine CD4+ T cells (4, 27). CD4+ T cells that migrated to the lower chamber during the 90-min incubation at 37˚C were quantified by flow cytometry using a bead standard (15-μm polystyrene beads; Polysciences). Frequencies of cytokine-producing CD4+ T cells were determined in input and migrated wells by intracellular staining (described later) to calculate percent migration of total IFN-γ- and IL-17+ CD4+ T cells.

Induction of skin inflammation in sheep and mice, and T cell egress assay

Chronic skin inflammation was induced in sheep by s.c. injection of 0.3–0.5 ml CFA (Sigma-Aldrich), emulsified at 1:1 with saline, into two sites in the area of the flank (9). Three or more weeks later, lymph vessels draining the inflamed skin and the control side were cannulated and lymph-borne CD4+ T cells were analyzed. To elicit inflammation in mice and to test T cell egress from the site, we modified a model of delayed hypersensitivity as described previously (28). Unless otherwise indicated, responder (OTII) Th1 cells and Ag-pulsed BMDCs generated from wild-type (WT) or CCL19-deficient pIIi mice were cocultured at a 2:1 ratio, keeping APCs constant at 2 × 10^5 cellsrecipient. After 1 h, the APC–T cell mixture was injected s.c. in 10 μl PBS into the footpads of recipient mice, and tissue swelling was blindly measured over time using an engineer’s caliper (Fisher Scientific). Swelling was defined as the footpad thickness after injection of cells subtracted by preinjection values for the same foot. In T cell egress assays, 20–70 h postinjection of 4–6 × 10^5 responder Th1 cell subsets and 1 × 10^6 Ag-loaded APCs, the draining and nondraining (control) popliteal lymph nodes and spleens of recipient mice were analyzed for donor cells based on fluorescent and/or congenic labels, as well as with APCs pulsed with OVA or a control protein (BSA) before transfer into the footpads of recipient mice. As done previously (4, 9, 27), we assessed T cell tissue egress by enumerating donor T cells that had left the skin and migrated into the popliteal draining lymph node (dLN) (Fig. 1B, 1C). Although at 20 h after transfer many donor Th1 cells had egressed from the inflamed site and reached the dLN, transferred cells in the contralateral lymph node or the spleen were below the level of detection (Fig. 1B, 1C, and data not shown), confirming migration via afferent lymph before transferred cells enter the blood circulation. In the presence of OVA-pulsed APCs, the number of OTII Th1 cells that left the site of inflammation and reached the dLN was drastically reduced relative to that of polyvalent Th1 cells (~75% reduction on average; p < 0.0001; Fig. 1C). We conclude that Ag recognition leads to downregulation of effector CD4+ T cell egress from inflamed tissue.

Ccr7+ enhances effector T cell egress from inflamed tissue and accelerates resolution of inflammation

To address whether tissue exit receptors can be targeted to modulate tissue egress of Ag-responding proinflammatory T cells, we generated Th1 cells from OTII mice and OTII mice whose T cells are Ccr7−/−. Ccr7−/− OTII Th1 cells showed a more uniformly high CCR7 expression relative to Ccr7WT OTII Th1 cells (Fig. 2A).
These Th1 cell subsets were differentially labeled with fluorescent dyes and, after coincubation with OVA-pulsed APCs, coinjected into the footpads of recipient mice. Strikingly, Ccr7\(^{TG}\) OTII Th1 cells showed a significantly enhanced capacity to egress from the inflamed skin and enter the dLN 20 h after transfer relative to Ccr7\(^{WT}\) OTII Th1 cells (\(p = 0.0002\); Fig. 2B, 2C). At this time point after cell transfer, both Ccr7\(^{TG}\) and Ccr7\(^{WT}\) Th1 cells were below the level of detection in spleens and contralateral lymph nodes (data not shown), confirming that cells had reached the dLN through the afferent lymph. Migratory differences were independent of the cell labels, because there were no differences in the migration of differentially labeled Ccr7\(^{WT}\) OTII Th1 cells (Fig. 2B). At this time point, we could not detect differences in cell proliferation or survival between Ccr7\(^{WT}\) and Ccr7\(^{TG}\) OTII cells in skin or dLN (Supplemental Fig. 1A–C). The Ccr7 transgene did not affect differentiation into Th1 cells as indicated by similar cytokine expression profiles after stimulation with OVA-pulsed APCs or PMA and ionomycin before injection (Fig. 2D and data not shown) and after restimulation of transferred Th1 cells recovered from skin (Supplemental Fig. 1D). Strikingly, although both Th1 cell subsets initially induced a similar magnitude of inflammation, resolution of inflammation was accelerated in mice that had received Ccr7\(^{TG}\) OTII Th1 cells (Fig. 2E). We conclude that enhancing exit receptor expression is able to dislodge effector T cells from inflamed tissue and speeds the resolution of inflammation.

**FIGURE 2.** CCR7\(^{TG}\) enhances effector T cell egress from inflamed tissue and accelerates resolution of inflammation. (A–C) CFSE-labeled Ccr7\(^{WT}\) or Ccr7\(^{TG}\) OTII Th1 cells were mixed with eFluor705-labeled Ccr7\(^{WT}\) OTII Th1 cells and incubated with OVA-pulsed APCs, before injection into the footpads of WT recipients. Twenty hours later, dLNs were analyzed for donor cells. (A) Representative CCR7 staining of Th1 cells before injection. (B) Quantification of donor Th1 cells that migrated to the dLN. (C) Tissue egress of CFSE-labeled Ccr7\(^{WT}\) and Ccr7\(^{TG}\) OTII Th1 cells relative to eFluor705-labeled Ccr7\(^{WT}\) OTII Th1 cells. Data are expressed as a percentage of the mean ratio of migrated OTII Th1 cells to polyclonal Th1 cells in the presence of BSA (set as 100%). Data points indicate individual recipients and the mean ± SEM of each group. (D) Intracellular cytokine profile of in vitro–generated Ccr7\(^{WT}\) OTII and Ccr7\(^{TG}\) OTII Th1 cells before injection with or without stimulation with OVA-pulsed APCs. (E) Ccr7\(^{WT}\) OTII or Ccr7\(^{TG}\) OTII Th1 cells were coincubated with OVA-pulsed APCs, injected into the footpads of separate groups of mice, and inflammation was measured over time. Data points depict individual recipients (B and C) and/or the mean ± SEM of each group (C and E). One experiment of \(n = 2\) with similar results (A, B, D, and E) or the combined analysis of all (\(n = 2\)) experiments (C) using five mice per group is shown. *\(p < 0.05\), **\(p < 0.005\).
Ag-sequestered effector T cells from inflamed tissue, translating into faster resolution of inflammation.

Lack of T cell CCR7 enhances local tissue inflammation

Next, we analyzed in vitro polarized Th1 cells from Cer7−/− OTII and Cer7WT OTII mice (Fig. 3A), which produced cytokines at similar frequency after stimulation with OVA-pulsed APCs or PMA and ionomycin (Fig. 3B and data not shown). Consistent with CCR7 as a major exit receptor (4, 5, 9), Cer7−/− Th1 cells were drastically reduced in the dLN relative to Cer7WT Th1 cells ($p = 0.0159$) and below the level of detection in the spleens of most recipients even 3 d after transfer together with OVA-loaded APCs into footpad skin (Fig. 3C and data not shown). These results are in line with data showing that lack of T cell CCR7 promotes T cell retention at effector sites (11, 16, 17, 29). Importantly, the reduced egress of Cer7−/− OTII Th1 cells from the site of inflammation translated into enhanced and prolonged inflammation in our hypersensitivity model (Fig. 3D). Together with our findings that enhancing T cell egress alleviates the inflammatory response (Fig. 2E), we conclude that the tissue egress capacity of effector T cells is a critical determinant of the course of inflammation and that tissue exit receptors can be targeted to modulate inflammation.

The CCR7–CCL21 axis is active in tissue egressing proinflammatory T cells

If the CCR7–CCL21 axis is a physiological target relevant to the egress of proinflammatory T cells, then effector T cells that have entered the afferent lymph draining inflamed sites should be responsive to CCR7 ligand. Because analysis of afferent lymph T cells is not feasible in mice and humans, the sheep has emerged as a classical model of afferent lymph cannulation, allowing for the analysis of tissue-recirculating lymphocytes (1, 4, 8, 30). Afferent lymph vessel cannulation in sheep revealed that lymph-borne IFN-γ+ Th1 and IL-17+ Th17 cells egressing from uninflamed or chronically inflamed skin migrated toward CCL21 in an ex vivo chemotaxis assay (Fig. 4). We conclude that the CCR7–CCL21 axis is not only active in adoptively transferred effector T cells but is also a physiological target in proinflammatory T cells that recirculate through extralymphoid sites.

Discussion

In this article, we demonstrate that the magnitude and duration of T cell–mediated inflammation is a function of the capacity of proinflammatory T cells to leave the inflamed tissue via the afferent lymph. This fills an important gap in our knowledge regarding the regulation of T cell–driven inflammation and highlights the importance of studies delineating the mechanisms that regulate T cell egress versus retention.

We found that CD4+ effector T cells that recognize Ag at the inflamed site greatly reduce their egress from the tissue (Fig. 1). This is in agreement with data demonstrating that upon antigenic stimulation in situ, virus-specific CD8+ T cells decrease their egress from the lung during influenza virus infection (10) and/or develop into long-term TRM in the vesicular stomatitis virus–infected brain (31). Because T cell entry into tissues is independent of Ag specificity (32), enhancing the retention of Ag-specific T cells by decreased egress from sites of inflammation and infection ensures continued T cell effector functions, while allowing
bystander T cells to egress and redistribute. Notably, also, long-term retention of CD4+ T cells as TBM at effector sites was proposed to involve antigen stimulation (33). In contrast, formation of CD8+ TBM requires additional or alternative Ag-independent, cytokine-dependent transcriptional reprogramming (reviewed in Refs. 34, 35).

Importantly, we show that tissue exit receptors can be targeted to modulate inflammation: transgenic expression of T cell CCR7 enhanced egress and accelerated resolution of inflammation, whereas lack of T cell CCR7 exacerbated inflammation. These data are consistent with reduced delayed hypersensitivity responses in Ccr7−/− mice, a phenotype that was attributed to effector T cell redistribution to the splenic white pulp (19). We demonstrate that an additional or alternative explanation is that Ccr7−/− effector T cells may enter inflamed tissues but egress prematurely via afferent lymph, thereby dampening local inflammation. This is likely accomplished by enhanced infiltrate clearance and/or limited access to Ag-bearing APCs at the effector site. Thus, enhancing T cell egress or preventing reduced egress from the effector site represents a novel potential target of anti-inflammatory therapy.

The finding that the CCR7-CL21 axis is active in physiologically recirculating effector T cells that have entered the inflammation-draining afferent lymph (Fig. 4) highlights the potential importance of this receptor-ligand pair as a therapeutic target. Although many inflammatory signals upregulate lymphatic CL21 at effector sites, its expression levels, as well as that of other lymphatically expressed chemokines and adhesion molecules, are strongly stimulus-dependent during inflammation (reviewed in Ref. 36). Because we show that diminished T cell egress exacerbates inflammation, future studies will be critical to reveal the regulation of CCL21 on lymphatic endothelial cells and CCR7 on tissue-infiltrating T cells in addition to identifying alternative tissue exit receptors active in different types of inflammation.

Dampening inflammation by guiding proinflammatory T cells out of the inflamed site adds to the various anti-inflammatory functions of lymphatic endothelial cells (reviewed in Ref. 21). One example of counterregulation of inflammation by lymphatic endothelial cells is the expression of atypical chemokine receptor 2 (D6), which scavenges inflammatory chemokines while preventing their expression at endothelial cells is the expression of atypical chemokine receptor 2 (D6), which scavenges inflammatory chemokines while precluding their expression at endothelial cells (21-23). Other examples demonstrate that lymphatic endothelial cells express CCL21 at effector sites, its expression levels, as well as that of other lymphatically expressed chemokines and adhesion molecules, are strongly stimulus-dependent during inflammation.

References


Disclosures

The authors have no financial conflicts of interest.


